NCT06747923
SB17170 Phase 2 Trial in IPF Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 22 words Show 7 more changesShow less
- Trial completed
- Primary completion date changed from estimate of May 30, 2026 to Jul 21, 2026
- Enrollment target: estimated 30 to confirmed 32
- Study completion date changed from estimate of Oct 31, 2026 to Jul 28, 2026
- Secondary endpoints: details revised at 3 of 5 entries
- Study description revised
- Site details revised at 5 of 5 sites
- Minor Primary completion date: Apr 7, 2026 to May 30, 2026v7
- Minor Study description revisedv6
- Minor Start date: Dec 30, 2024 to Jan 27, 2025v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 5 of 5 sites
- Minor Study description shortened, about 3 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from baseline in FVC (ml)
Timeframe: Week 12
Secondary (3)
Change from baseline in FVC (%)
Change from baseline in DLCO
Change from baseline in quality of life and symptoms
Arms and interventions
SB17170 of A mg, Single doseExperimental
SB17170 of B mg, Single doseExperimental
PlaceboPlacebo comparator
Drugs: SB17170, Placebo
Sites
5 sites in 1 country